|
| |
Physician Office Laboratory (POL) Testing Markets Worldwide: Status Quo and Future Trends
|
Published: Nov 2010 | Pages: 250 | Pub ID: MM1302869967 |
|
|
|
 |
This report is the second edition of the report “Physician Office Testing, Worldwide: Status Quo and Future Trends” that was first published in 2007. The report concentrates on how the market for POL testing has evolved from 2007 to 2010.
The report takes a bold look into the technologies and trends in physician office testing and laboratories (POLs) with a special focus on the economics of test use in on-site patient care. The report is conservative in its predictions and offers a calculated look into the future, based on events taking place in the present.
The term physician office lab (POL) is as wide and diverse as one can imagine. It encompasses physician practices as small as 2 to 5 doctors that perform a few rapid tests to large practices of some 200 physicians that operate labs similar to small hospital laboratories. The definition used here is therefore broad and refers to the market for tests which are: Performed in a physician office setting, At the time of a consultation between a physician or other healthcare professional (nurse practitioner, pharmacist, provides a result to be used during the medical visit and, is used for screening, diagnosis or monitoring purposes. Growth in physician office testing is fueled by trends in preventative medicine and proactive approaches in treating the increasing number of diagnosed diabetics; by the globalization of infectious diseases and the associated public health issues; and by the need to monitor the explosion of people with cardiovascular disease and other chronic conditions.
The report offers a quantitative assessment of specific markets, worldwide, in U.S. dollars for 2009 to 2014. This data is provided in order to set the status quo of tests and technologies. However the report concentrates on how these will impact the economics of healthcare over the near term and longer when possible.
This exhaustive report provides:
- Discussions of the Regulatory Environment for POLs in various countries and regions.
- The Top POL-conducted Tests and average reimbursement level.
- POL Test Revenues by Type of Test, 2009-2014, for more than 35 test segments.
- POL Test Revenues by Region (Europe, Asia, US) , 2009 to 2014.
- Breakout of the Number of POLSin the US by type (CLIA-waived, non-waived)
- Complete discussions of the POL environments in top geographic markets.
- Profiles of the POL Offerings of over 75 suppliers.
- Market Analyses for Key POL Testing Areas.
- Chemistry panels
- Coag PT
- Lipids
- Hemato - CBC
- Glucose
- HbA1c
- Rapid Flu
- Anemia ferritin, iron
- Preg/LH
- Urinalysis
- PSA
- TSH
- FOB
- Cardiac Markers
- Hepatitis
- HIV
- Histology
- Microbiology culture
- Atrep A
- Autoimmune
- Sed rate
- H. pylori
- Cancer Markers
- CRP
- Hgb
- Respiratory Viruses
- STDs
- Allergy
- DAU
- Infectious diseases
- Microalbumin
- TDM
- Other
including:
The world market for the POL sector of point-of-care diagnostics is provided in U.S. dollars for the years 2009 - 2014. No adjustments have been made to the market data for the effects of currency exchange fluctuations or inflation. This may seem problematic, given the drastic devaluation of the U.S. dollar versus the Japanese Yen, euro and Swiss Franc. Kalorama has decided to use a constant exchange rate because it is a more accurate reflection of actual revenue growth in dollars rather than growth due to exchange rate fluctuations. |
|
| By: Kalorama Information |
|
|
| |
|
|
|
US Office
India Office